Should You Buy The Dogs Of The FTSE For 2015? Royal Dutch Shell Plc, GlaxoSmithKline plc, Standard Chartered PLC, Direct Line Insurance Group PLC And Admiral Group plc

Royal Dutch Shell Plc (LON:RDSB), GlaxoSmithKline plc (LON:GSK), Standard Chartered PLC (LON:STAN), Direct Line Insurance Group PLC (LON:DLG) and Admiral Group plc (LON:ADM) could all beat the market in 2015.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

This is the second part of my two-part series looking at the 10 FTSE 100 stocks that qualify for a UK version of the popular Dogs of the Dow high-yield investment strategy.

The Dogs strategy involves buying the 10 highest-yielding stocks in the index at the start of the year, and then selling them at the end of the year. In the US, the Dogs strategy has beaten the Dow in two of the last three years.

Here are the final five 2015 Dog stocks from the FTSE 100 (if you missed the first five stocks, you can catch up here):

Company

2015 prospective yield

Royal Dutch Shell (LSE: RDSB)

5.9%

GlaxoSmithKline (LSE: GSK)

5.9%

Standard Chartered (LSE: STAN)

6.0%

Direct Line Insurance Group (LSE: DLG)

7.4%

Admiral Group (LSE: ADM)

6.9%

Shell

No-one quite knows how the oil market will behave next year.

However, Shell should be able to afford to ride out the storm, thanks to its huge scale, large gas business and low debt levels.

Although cash flow could come under pressure next year, the firm’s forecast P/E of 9.8 suggests to me that Shell remains a safe income buy.

GlaxoSmithKline

Allegations of bribery and corruption, patent expiries, and falling profits.

It’s been a poor year for Glaxo, but this has left the UK’s largest pharmaceutical firm trading with a prospective yield of nearly 6% and a planned 82p per share capital return in 2015.

Glaxo remains in my portfolio, and on my buy list.

Standard Chartered

Shares in Asia-focused Standard Chartered have fallen by around 35% this year, amid a constant run of downgraded forecasts.

As a result, the bank’s shares trade on a 2015 forecast P/E of just 8.1, which prices in a lot of bad news, in my view. A prospective yield of around 5.9% should also reward patient investors.

Direct Line

Direct Line makes it into the Dogs of the FTSE thanks to a generous special dividend policy, which gives the firm’s shares a prospective yield of 7.4%, the highest in this group.

The fall in motor insurance premiums does seem to be slowing, so 2015 could be a reasonable year for Direct Line.

Admiral

As with Direct Line, it’s important to remember that these insurers’ generous yields are driven by special dividends, which are currently being paid every year, but may not be in the future.

That aside, Admiral’s 2015 forecast P/E of 14.2 reflects the fact that earnings per share are expected to fall by around 8% next year, raising the risk that dividend growth could also stall.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head owns shares in Royal Dutch Shell and GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

If I’d put £5,000 in Nvidia stock at the start of 2024, here’s what I’d have now

Nvidia stock was a massive winner in 2023 as the AI chipmaker’s profits surged across the year. How has it…

Read more »

Light bulb with growing tree.
Investing Articles

3 top investment trusts that ‘green’ up my Stocks and Shares ISA

I’ll be buying more of these investment trusts for my Stocks and Shares ISA given the sustainable and stable returns…

Read more »

Investing Articles

8.6% or 7.2%? Does the Legal & General or Aviva dividend look better?

The Aviva dividend tempts our writer. But so does the payout from Legal & General. Here he explains why he'd…

Read more »

a couple embrace in front of their new home
Investing Articles

Are Persimmon shares a bargain hiding in plain sight?

Persimmon shares have struggled in 2024, so far. But today's trading update suggests sentiment in the housing market's already improving.

Read more »

Market Movers

Here’s why the Unilever share price is soaring after Q1 earnings

Stephen Wright isn’t surprised to see the Unilever share price rising as the company’s Q1 results show it’s executing on…

Read more »

Investing Articles

Barclays’ share price jumps 5% on Q1 news. Will it soon be too late to buy?

The Barclays share price has been having a great time this year, as a solid Q1 gives it another boost.…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

The AstraZeneca share price lifts 5% on a top-and-bottom earnings beat

The AstraZeneca share price reached £120 today and helped push the FTSE 100 higher. Would I still buy this flying…

Read more »

Young black woman using a mobile phone in a transport facility
Market Movers

Meta stock slumps 13% after poor results. Here’s what I’ll do

Jon Smith flags up the reasons behind the fall in the Meta stock price overnight, along with his take on…

Read more »